Compare SPE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SPE | MDXH |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.8M | 183.4M |
| IPO Year | N/A | 2021 |
| Metric | SPE | MDXH |
|---|---|---|
| Price | $14.08 | $3.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 44.8K | ★ 97.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.31 |
| Revenue Next Year | N/A | $18.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.72 | $1.36 |
| 52 Week High | $15.99 | $5.33 |
| Indicator | SPE | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 26.68 | 46.21 |
| Support Level | $13.95 | $3.05 |
| Resistance Level | $15.59 | $3.78 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 10.40 | 26.36 |
Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.